Hagen Kennecke

Hagen Kennecke: First prospective trial to confirm benefit of adjuvant COX-2 in PIK3CA activated colon cancer

Hagen Kennecke, Section chief and Chief Health Officer of the OHSU Knight-Legacy Health Cancer Collaborative, shared a post on X:

”First prospective trial to confirm benefit of adjuvant COX-2 in PIK3CA activated colon cancer, OS HR=0.4.

Patients are asking: do we recommend COX-2 for the 20% with mutation PIK3CA? 

Need to do NGS for all stage III CRC.”

Source: Hagen Kennecke/X

Anthony F Shields Ardaman Shergill Benjamin Tan cancer Chao Ma Charles S Fuchs Colon cancer Eileen M. O'Reilly Felix Couture Hagen Kennecke James Knight Jeffrey A Meyerhardt Jonathan A Nowak Juha Väyrynen Kenji Fujiyoshi Koichiro Haruki Melissa Zhao OncoDaily Oncology Pankaj Kumar Philip Kuebler Philip Philip Qian Shi Shrikant Mane Shuji Ogino Smitha Krishnamurthi Tyler Twombly